Stem cells, cell therapies, and bioengineering in lung biology and disease 2021
Year: 2022
Type: article
Abstract: The 9th biennial conference titled “Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases” was hosted virtually, due to the ongoing COVID-19 pandemic, in collaboration with the University of Vermont Larner College of Medicine, the National Heart, Lung, and Blood Institute, the Alpha-1 Foundation, the Cystic Fibrosis Foundation, and the International Society for Cell & Gene Therapy. The event was held from July 12th through 15th, 2021 with a pre-conference workshop held on July 9th. As in previous years, the objectives remained to review and discuss the status of active research areas involving stem cells (SCs), cellular therapeutics, and bioengineering as they relate to the human lung. Topics included 1) technological advancements in the in situ analysis of lung tissues, 2) new insights into stem cell signaling and plasticity in lung remodeling and regeneration, 3) the impact of extracellular matrix in stem cell regulation and airway engineering in lung regeneration, 4) differentiating and delivering stem cell therapeutics to the lung, 5) regeneration in response to viral infection, and 6) ethical development of cell-based treatments for lung diseases. This selection of topics represents some of the most dynamic and current research areas in lung biology. The virtual workshop included active discussion on state-of-the-art methods relating to the core features of the 2021 conference, including in situ proteomics, lung-on-chip, induced pluripotent stem cell (iPSC)-airway differentiation, and light sheet microscopy. The conference concluded with an open discussion to suggest funding priorities and recommendations for future research directions in basic and translational lung biology.
Authors: Laertis Ikonomou, Mattias Magnusson, Ruben Dries, Erica L. Herzog, Robert E. Hynds, Zea Borok, Jin-Ah Park, Steven Skolasinski, Janette K. Burgess, Leigh Turner, Sarah M. Mojarad, John E. Mahoney, Thomas Lynch, Mareike Lehmann, Victor J. Thannickal, Jamie L. Hook, Andrew E. Vaughan, Evan T. Hoffman, Daniel J. Weiss, Amy L. Ryan
Institutions: University at Buffalo, State University of New York, Lund University, Boston University, Yale University, University College London, University of California San Diego, Harvard University, University of Minnesota, University Medical Center Groningen, University of Groningen, University of California, Irvine, University of Southern California, Cystic Fibrosis Foundation, University of Iowa, University of Iowa Health Care, Helmholtz Munich, Tulane University, Icahn School of Medicine at Mount Sinai, University of Pennsylvania, University of Vermont
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: U.S. Department of Veterans Affairs, Cystic Fibrosis Foundation, Alpha-1 Foundation, United Therapeutics Corporation, Wellcome Trust, University of Vermont, National Institutes of Health, Medical Research Council, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Center for Advancing Translational Sciences
Awards: G1044130170, G1206087605, Harnessing pre-clinical lung cancer patient models for precision immuno- oncology, G336615015, G3486068591, G3850548428, Lung Allograft Stem Cell Regeneration and Immune Destruction, Harvard Chan School NIEHS Center for Environmental Health, G5337825365, G5385979215, Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Lung Diseases, G6764111060, Yale Clinical and Translational Science Award, Precision Medicine Center for Cystic Fibrosis
OpenAlex ID: W4283641511